{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:39:30Z","timestamp":1786700370476,"version":"build-2736575974"},"reference-count":113,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/14712598.2026.2703858","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:45:30Z","timestamp":1783770330000},"page":"665-676","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma"],"prefix":"10.1080","volume":"26","author":[{"given":"Manraj Singh","family":"Sra","sequence":"first","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_5_5_1","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528.","journal-title":"Hemasphere"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071686"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.11.1693"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00639-z"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00653-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60980-2"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7"},{"key":"e_1_3_5_28_1","unstructured":"Allogene therapeutics receives FDA orphan-drug designation for ALLO-605 its first TurboCARTM T cell product Candidate for the treatment of multiple myeloma. Allogene Therapeutics [Internet]. [cited 2026 Apr 18]. Available from: https:\/\/ir.allogene.com\/news-releases\/news-release-details\/allogene-therapeutics-receives-fda-orphan-drug-designation-allo\/"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142695"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-7644"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198499"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04244-6"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220145110"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00580"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565407"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286118"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_3_5_43_1","unstructured":"FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma. FDA [Internet]. [cited 2026 Apr 18]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2603870"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2299"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199733"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-697"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0278-7"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00330-4"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2373331"},{"key":"e_1_3_5_61_1","unstructured":"Richard S Orlowski RZ Kaufman J et al. The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising data in relapsed\/ refractory multiple myeloma in a phase 1\/2A clinical trial as it advances into cohort 7. EHA-4604. 2025 [Internet]. [Jun 13 [cited 2026 Apr 18]. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160156\/shambavi.richard.the.anti-bcma.antibody-drug.conjugate.hdp-101.with.a.novel.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31552%2Amarker%3D5844%2Afeatured%3D19595"},{"key":"e_1_3_5_62_1","article-title":"Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma","author":"Maura F","year":"2025","unstructured":"Maura F, Freeman CL, Maclachlan KH, et al. Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma. bioRxiv. 2025.","journal-title":"bioRxiv"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201044"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141077"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023557"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0005"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024965"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029921"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00763-8"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.019"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp6667"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01277"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015008"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70218"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0408"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031439"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01730"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02767-w"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030027"},{"key":"e_1_3_5_95_1","unstructured":"Long-term follow-up results of a multicenter first-in-human study\u2026 - Du J - EHA-1911. 2021 [Internet]. [Jun 9 [cited 2026 Apr 18]. Available from: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/325720\/juan.du.long-term.follow-up.results.of.a.multicenter.first-in-human.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dcar-t"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970380.84060.bf"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166994"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136985"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303194"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"e_1_3_5_104_1","unstructured":"Study details | NCT06465316 | testing teclistamab (TECVAYLI) in combination with iberdomide for relapsed or refractory multiple myeloma | ClinicalTrials.Gov [Internet]. [cited 2026 Apr 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06465316"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-25-0372"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44040098"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016712"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204270"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604657"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.054"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2703858","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2703858","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2703858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:18:44Z","timestamp":1786699124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2703858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":113,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/14712598.2026.2703858"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2703858","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}